People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ray Therapeutics, Inc. | — | Biotechnology | Series A | $20.0M | $126.7M | 2021 |
| jCyte, Inc. | — | Other | Seed | $3.9M | $71.8M | 2019 |
Paul Bresge at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Bresge on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tiba Aynechi | 1 | 9 |
| Sean Ainsworth | 1 | 5 |
| Raymond Camahort | 1 | 4 |
| Andrew Howard | 1 | 4 |
| Dmitry Kuzmin | 1 | 3 |
| Gary Abrams | 1 | 2 |
| Hannah Chang | 1 | 2 |
| Cameron Gallagher | 1 | 1 |
| Henry Klassen | 1 | 1 |
| Terry O'Neal | 1 | 1 |
| Jing Yang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.